Login to Your Account



Washington Roundup

FDA to Silence 'Noise' from too Many Adverse Events

By Mari Serebrov


Monday, March 28, 2011
WASHINGTON – Things should be a little quieter at the FDA this week as new safety reporting requirements go into effect to reduce the "noise" from the overreporting of individual serious adverse events in clinical trials

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription